STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
The phase 3 STELLAR-303 trial demonstrated a significant overall survival benefit of zanzalintinib plus atezolizumab over regorafenib in refractory microsatellite-stable (MSS) metastatic colorectal ca
APA
Bando H, Yoshino T (2026). STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer.. Med (New York, N.Y.), 7(1), 100957. https://doi.org/10.1016/j.medj.2025.100957
MLA
Bando H, et al.. "STELLAR-303: Breaking the immunotherapy wall in MSS colorectal cancer.." Med (New York, N.Y.), vol. 7, no. 1, 2026, pp. 100957.
PMID
41519113 ↗
Abstract 한글 요약
The phase 3 STELLAR-303 trial demonstrated a significant overall survival benefit of zanzalintinib plus atezolizumab over regorafenib in refractory microsatellite-stable (MSS) metastatic colorectal cancer, marking the first phase 3 success of an immunotherapy-based regimen in this population. These results may reshape treatment paradigms and renew interest in biomarker-guided immunotherapy for MSS disease.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.